HCW Biologics (HCWB) Stock Price, News & Analysis

Company Overview

HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.

Key Stats

• Today's Range: $0.38 to $0.44
• 50-Day Range: $0.29 to $1.24
• 52-Week Range: $0.28 to $2.52
• Volume: 355,161 shs
• Average Volume: 2.41 million shs
• Market Capitalization: $15.89 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

HCW Biologics Stock Analysis - MarketRank™

HCW Biologics scored higher than 6% of companies evaluated by MarketBeat, and ranked 925th out of 948 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for HCW Biologics.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of HCW Biologics is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of HCW Biologics is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

HCW Biologics has a P/B Ratio of 1.14. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.18% of the float of HCW Biologics has been sold short.

Short Interest Ratio / Days to Cover

HCW Biologics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in HCW Biologics has recently increased by 80.06%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

HCW Biologics does not currently pay a dividend.

Dividend Growth

HCW Biologics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.18% of the float of HCW Biologics has been sold short.

Short Interest Ratio / Days to Cover

HCW Biologics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in HCW Biologics has recently increased by 80.06%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: 0.00

News Sentiment

HCW Biologics has a news sentiment score of 0.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for HCW Biologics this week, compared to 0 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, HCW Biologics insiders have not sold or bought any company stock.

Percentage Held by Insiders

49.90% of the stock of HCW Biologics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 2.96% of the stock of HCW Biologics is held by institutions.

HCWB Stock Analysis - Frequently Asked Questions

How have HCWB shares performed this year?

HCW Biologics' stock was trading at $1.2250 on January 1st, 2024. Since then, HCWB stock has decreased by 65.7% and is now trading at $0.42.
View the best growth stocks for 2024 here.

When did HCW Biologics IPO?

HCW Biologics (HCWB) raised $45 million in an initial public offering (IPO) on Tuesday, July 20th 2021. The company issued 5,600,000 shares at a price of $8.00 per share. EF Hutton served as the underwriter for the IPO and Revere Securities was co-manager.

How do I buy shares of HCW Biologics?

Shares of HCWB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of HCW Biologics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that HCW Biologics investors own include Jiuzi (JZXN), Faraday Future Intelligent Electric (FFIE), AMC Entertainment (AMC), Kiora Pharmaceuticals (KPRX), Rallybio (RLYB), Adial Pharmaceuticals (ADIL) and Aridis Pharmaceuticals (ARDS).

Company Calendar

• Today: 12/27/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:HCWB
• CUSIP: N/A
• CIK: 1828673
• Web: www.hcwbiologics.com
• Phone: 954-842-2024
• Fax: 954-842-2037
• Employees: 40
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($1.00)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-24,990,000.00
• Net Margins: -1,067.82%
• Pretax Margin: -1,067.79%
• Return on Equity: -2,516.84%
• Return on Assets: -132.95%

Debt

• Debt-to-Equity Ratio: 0.95
• Current Ratio: 0.07
• Quick Ratio: 0.07

Sales & Book Value

• Annual Sales: $3.50 million
• Price / Sales: 4.54
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.37 per share
• Price / Book: 1.14

Miscellaneous

• Outstanding Shares: 37,823,000
• Free Float: 18,949,000
• Market Cap: $15.89 million
• Optionable: Not Optionable
• Beta: 0.88